FDA Approves SILIQ — Bausch Health US LLC

Bausch Health US LLC secured FDA approval for the subcutaneous formulation of Brodalumab under the brand SILIQ, a move expected to significantly diversify its biologic portfolio and bolster its competitive standing in the moderate-to-severe psoriasis market. This clearance validates the company’s post-acquisition commercial strategy and positions Bausch Health to capture market share within the rapidly growing immunology sector.